Laura E. Niklason Sells 261,369 Shares of Humacyte, Inc. (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA) CEO Laura E. Niklason sold 261,369 shares of the business’s stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the sale, the chief executive officer now owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. The trade was a 13.12 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Humacyte Trading Up 2.5 %

NASDAQ HUMA opened at $4.49 on Friday. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte, Inc. has a 1-year low of $2.43 and a 1-year high of $9.97. The firm’s fifty day simple moving average is $5.33 and its 200-day simple moving average is $6.17. The company has a market capitalization of $565.11 million, a PE ratio of -3.27 and a beta of 1.47.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a “neutral” rating in a report on Friday, October 18th. Benchmark reissued a “buy” rating and set a $15.00 target price on shares of Humacyte in a research note on Thursday, October 10th. TD Cowen reaffirmed a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research report on Friday, October 18th. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 price objective on shares of Humacyte in a research report on Wednesday, November 13th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Humacyte currently has an average rating of “Buy” and an average price target of $11.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of HUMA. Vanguard Group Inc. lifted its holdings in shares of Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after buying an additional 896,415 shares during the last quarter. Anson Funds Management LP acquired a new stake in Humacyte in the first quarter valued at approximately $156,000. Virtu Financial LLC acquired a new stake in Humacyte in the first quarter valued at approximately $197,000. ARS Investment Partners LLC bought a new stake in Humacyte in the second quarter worth approximately $559,000. Finally, Bank of New York Mellon Corp increased its stake in shares of Humacyte by 62.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock worth $1,219,000 after purchasing an additional 97,931 shares during the last quarter. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.